← All trials
NCT06667999
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2025
- Primary completion
- Dec 31, 2035
- Completion date
- Dec 31, 2035
- First posted
- Oct 31, 2024
- Last posted
- Oct 31, 2024
- Enrollment
- 10000
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- Government of DenmarkCollaborator
- Karolinska InstituteCollaborator
- Region ZealandCollaborator
- Steno Diabetes Center CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- Aarhus UniversityCollaborator
- Gødstrup HospitalCollaborator
- University of GroningenCollaborator
- University of Southern DenmarkCollaborator
- University of Southern DenmarkCollaborator
- University of BaselCollaborator
- Viborg Regional HospitalCollaborator
- University of OsloCollaborator
- Aalborg UniversityCollaborator
- Randers Regional HospitalCollaborator
- University of TampereCollaborator
- Region SyddanmarkCollaborator
- University of CopenhagenSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.